Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Takeda Sees Another Wave 1 Plan Come Crashing Down

Sep 02 2021

• By Joseph Haas

Leukemia — Takeda's NEDD8 inhibitor failed a Phase III study in MDS and leukemia

Related Content

Keeping Track: US FDA Approves Heron’s Zynrelef In Post-Op Pain; Amgen/AZ Submit Tezepelumab For Severe Asthma

May 15 2021

Takeda: 12 NMEs Poised To Launch In Five Years, And Deliver $10 Bn In Peak Sales

Nov 19 2019

Takeda Looks To Ride 'Wave 1' To JPY5tn Target

Dec 09 2020

ASCO 2020: Pevonedistat Shows Promise In Higher-Risk MDS

Jun 02 2020

Takeda’s Andy Plump Tells The Japanese Pharma’s New Story

Feb 23 2021

Related Companies

Takeda Pharmaceutical Co. Ltd.

Bristol Myers Squibb Company

Merck & Co., Inc.

Additional Topics

Clinical Trials Research & Development Business Strategies Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window